SEC Form 4 · accession 0001193125-26-259637
Aldeyra Therapeutics, Inc. · ALDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd C Brady
Officer — President and CEO · Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 5, 2026 · 4:19 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001341235
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 3, 2026 | P | 250,000 | $1.6738 | A | 1,721,298 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.64 to $1.70, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.